NewStem Ltd.
Ayelet Dilion-Mashiah is an experienced leader in the life sciences industry, currently serving as CEO of REMEDY CELL Ltd. since 2024. Prior to this role, Ayelet held the position of CEO at NewStem Ltd. from 2018 to 2023 and served as a consultant at Ayelet Dilion Mashiah Advisors Ltd. between 2016 and 2018. Ayelet's extensive career includes significant leadership roles such as CEO at BioMAS from 2011 to 2016 and CEO at Do-Coop Technologies Ltd. from 2007 to 2011. Earlier in the career, Ayelet was the Director of the Corporate Economic Department at Teva Pharmaceutical Industries Ltd in Israel from 2003 to 2007.
This person is not in any teams
This person is not in any offices
NewStem Ltd.
NewStem is a Jerusalem-based biotech with a novel precision-medicine technology that can increase chemotherapy's effectiveness. NewStem is a spinoff of Yissum, The Technology Transfer Company of The Hebrew University. NewStem's technology can predict patients' resistance to chemotherapy allowing for better, targeted cancertreatments and the potential to reduce resistance to chemotherapy.